Stockscreener 앱 받기
14.38
0.07%
0.01
시간 외 거래:
14.38
Amicus Therapeutics Inc 주식(FOLD)의 최신 뉴스
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week HighTime to Buy? - MarketBeat
FOLD Should I Buy - Intellectia AI
872,411 Shares in Amicus Therapeutics, Inc. $FOLD Acquired by Ion Asset Management Ltd. - MarketBeat
Iron Triangle Partners LP Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside - Yahoo Finance
Amicus Therapeutics stock hits 52-week high at 14.38 USD By Investing.com - Investing.com Nigeria
Elevation Point Wealth Partners LLC Makes New Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) Valuation After Strong Recent Share Price Momentum - simplywall.st
Amicus Therapeutics, Inc. $FOLD Shares Sold by Prosight Management LP - MarketBeat
Avoro Capital Advisors LLC Decreases Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Assessing Amicus Therapeutics (FOLD) After Strong One Year Share Price Performance - simplywall.st
Amicus Therapeutics stock hits 52-week high at 14.38 USD - Investing.com India
Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion - MSN
Amicus Therapeutics (NASDAQ:FOLD) Reaches New 12-Month HighTime to Buy? - MarketBeat
Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis - PR Newswire
Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan’s Ministry of Health, Labour and Welfare (MHLW) - MSN
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin’s Rare Disease Portfolio - Yahoo Finance
Amicus Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus - Yahoo Finance
Bradley Campbell Sells 22,500 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Insider Sell: Bradley Campbell Sells 22,500 Shares of Amicus The - GuruFocus
Amicus Therapeutics (FOLD) CEO Bradley Campbell sells 22,500 shares in open market - Stock Titan
FOLD SEC FilingsAmicus Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan
FDA’s rare disease toolbox not fully used - BioWorld MedTech
JPMorgan Chase & Co. Has $16.68 Million Stock Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is It Too Late To Consider Amicus Therapeutics (FOLD) After The Proposed BioMarin Deal Price? - simplywall.st
Amicus Therapeutics shareholders approve acquisition by BioMarin Pharmaceutical - Investing.com
Amicus Stockholders Approve BioMarin Acquisition at Special Meeting - TipRanks
Shareholders back Amicus (NASDAQ: FOLD) sale to BioMarin Pharmaceutical - Stock Titan
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Biotech Sector with a 23.7% Revenue Growth - DirectorsTalk Interviews
Bradley Campbell sells 75,000 FOLD shares under 10b5-1 plan (FOLD) - Stock Titan
Vanguard Group Inc. Buys 126,441 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
Fox Run Management L.L.C. Takes $553,000 Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Primecap Management Co. CA Sells 128,200 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Amicus Therapeutics Experiences Revision in Stock Score Amid Mixed Financial Performance - Markets Mojo
BIOMARIN PHARMACEUTICAL INC SEC 10-K Report - TradingView
BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio - simplywall.st
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating Growth in Rare Diseases with Strong Revenue Momentum - DirectorsTalk Interviews
BioMarin Amicus Deal Shifts Rare Disease Portfolio And Valuation Focus - Yahoo Finance
Precision Trading with Amicus Therapeutics Inc. (FOLD) Risk Zones - Stock Traders Daily
BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results - The AI Journal
Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues - Finviz
Amicus Therapeutics: Q4 Earnings Snapshot - kare11.com
Amicus Therapeutics Q4 Highlights: Revenue Growth Amid Losses - Intellectia AI
Amicus Therapeutics: Fourth Quarter Financial Results Overview - Bitget
Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives - Sahm
Will Amicus Therapeutics Inc. benefit from sector rotationEarnings Overview Report & Daily Entry Point Alerts - mfd.ru
Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates - The Manila Times
1.20%
0.06%
자본화:
|
볼륨(24시간):